Mirtazapine — Informed Consent (Off‑label Low‑Dose Sleep & Mood Support)

INFORMED CONSENT FOR MIRTAZAPINE (OFF‑LABEL LOW‑DOSE SLEEP & MOOD SUPPORT)

§1 PURPOSE, CONTEXT, AND SCOPE

§1.1 This document constitutes an informed consent agreement between the Patient identified herein (the "Patient") and the Prescribing Physician acting on behalf of the Clinic. It documents that the Patient has received, understood, and accepted comprehensive information regarding the proposed off‑label use of mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), at low doses to support sleep quality, sleep architecture, and mild mood symptoms.

§1.3 Health optimization context: The Patient understands that the Clinic operates as a proactive health optimization / longevity practice. Quality sleep and psychological well‑being are foundational pillars of health. Low‑dose mirtazapine may be considered when behavioral interventions alone are insufficient and the Patient's clinical profile suggests benefit from pharmacological support.

§1.4 This consent is governed by the laws of Denmark and the European Union, including but not limited to the Danish Health Act (Sundhedsloven) and Regulation (EU) 2016/679 (General Data Protection Regulation).

§1.5 By signing this document, the Patient confirms they have had adequate time to read, consider, and ask questions, and that their questions have been answered to their satisfaction.

§3 MEDICATION, CLASS, AND DESCRIPTION OF TREATMENT

§3.1 Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). It works by blocking presynaptic alpha‑2 adrenergic receptors and certain serotonin receptors (5‑HT2A, 5‑HT2C, 5‑HT3), while also exerting potent antihistamine (H1) activity.

§3.2 At low doses (3.75–15 mg), the antihistamine effect predominates, producing significant sedation and promoting sleep without the stimulating noradrenergic effects seen at higher doses. This dose‑dependent pharmacology is the basis for off‑label use as a sleep aid.

§3.3 Low‑dose mirtazapine has been shown to improve sleep architecture, including increased slow‑wave (deep) sleep duration, which is critical for physical recovery, immune function, and memory consolidation.

§3.4 Brand names include Remeron and various generics. The medication is available as standard tablets and orodispersible (melt) tablets.

§4 REGULATORY STATUS AND OFF‑LABEL USE

§4.1 Mirtazapine is an EMA‑authorised and Danish Medicines Agency (Lægemiddelstyrelsen) approved medication for the treatment of major depressive episodes in adults.

§4.2 Off‑label use: The Patient understands that prescribing mirtazapine at low doses primarily for insomnia, sleep architecture improvement, or mild mood support in a health optimization context is not an EMA‑approved indication. Off‑label prescribing is a lawful and common medical practice when, in the clinician's judgment, it is appropriate and supported by clinical evidence or guidelines.

§4.3 The Patient understands that using mirtazapine for "sleep optimization," "sleep architecture improvement," or "mild mood support" within a longevity/health optimization practice is not itself an approved indication, and that specific outcomes cannot be guaranteed.

§5 EXPECTED BENEFITS (NO GUARANTEE)

§5.1 Potential benefits may include:

  • Improved sleep onset (reduced time to fall asleep)
  • Improved sleep architecture, including increased slow‑wave (deep) sleep
  • Improved sleep continuity and reduced nighttime awakenings
  • Mild anxiolytic effect and reduction in evening rumination
  • Improved mood and reduced symptoms of mild depression or low mood
  • Improved next‑day energy and cognitive function through better sleep quality

§5.2 The Patient understands that benefits are variable, not guaranteed, and depend on individual biology, dosing, concurrent medications, lifestyle, and the nature and severity of the underlying condition.

§5.3 The Patient understands that mirtazapine is being used as part of a comprehensive approach that may include behavioral sleep interventions (sleep hygiene, CBT‑I), circadian rhythm optimization, and lifestyle modifications.

§6 MATERIAL RISKS, SIDE EFFECTS, AND WARNINGS

§6.1 The Patient understands that all medicines carry risks. The following risks are material and may be serious. This list is not exhaustive.

§6.2 Common / expected adverse effects:

  • Sedation and drowsiness (most pronounced in the first days; typically the intended therapeutic effect at low doses)
  • Increased appetite and weight gain (a well‑documented effect; the Patient should monitor weight and discuss dietary strategies with the Clinic)
  • Dry mouth
  • Headache
  • Dizziness
  • Fatigue or lethargy (particularly if dose is too high or timing is suboptimal)
  • Vivid dreams (generally considered a sign of increased REM sleep)
  • Peripheral edema (mild fluid retention, uncommon at low doses)

§6.3 Next‑day sedation and impairment

Mirtazapine can cause residual drowsiness the following morning, particularly during the initial days of treatment or after dose increases. The Patient should:

  • Take the medication 30–60 minutes before intended bedtime
  • Ensure 7–8 hours of sleep opportunity
  • Not drive or operate machinery until they understand how the medication affects them

§6.4 Metabolic effects and weight gain

Weight gain and increased appetite are among the most common side effects. At low doses these effects may be less pronounced than at antidepressant doses, but individual responses vary. The Patient agrees to:

  • Monitor body weight regularly
  • Report significant weight changes to the Clinic
  • Discuss nutritional strategies to mitigate this effect

§6.5 Serotonin syndrome (rare but serious)

Although the serotonergic risk profile of mirtazapine is lower than SSRIs/SNRIs, serotonin syndrome can occur, especially in combination with other serotonergic medications. Symptoms may include:

  • Agitation, confusion, rapid heart rate
  • Muscle rigidity, tremor, incoordination
  • Hyperthermia (high body temperature)
  • Diarrhea

The Patient must seek emergency care immediately if these symptoms develop, particularly if taking other serotonergic medications.

§6.6 Hematological effects (very rare)

Mirtazapine has been associated in very rare cases with:

  • Agranulocytosis (severe drop in white blood cells)
  • Neutropenia
  • Bone marrow suppression

The Patient should report unexplained fever, sore throat, mouth ulcers, or signs of infection promptly, as these may indicate a blood count abnormality requiring urgent investigation.

§6.7 Psychiatric effects

  • Worsening of depression or suicidal ideation: Although mirtazapine is an antidepressant, paradoxical worsening of mood or emergence of suicidal thoughts can occur, particularly in the first weeks of treatment. The Patient must report any worsening mood, new anxiety, agitation, or suicidal thoughts immediately.
  • Mania or hypomania in patients with undiagnosed bipolar disorder
  • Restless legs (uncommon, may paradoxically worsen in some patients)

§6.8 Discontinuation effects

Although mirtazapine has a relatively mild discontinuation profile compared to SSRIs/SNRIs, abrupt cessation after regular use may cause:

  • Rebound insomnia
  • Nausea, dizziness
  • Anxiety, irritability
  • Headache

The Patient understands that mirtazapine should be tapered gradually under medical guidance rather than stopped abruptly.

§6.9 QT prolongation (rare)

Mirtazapine may, in rare cases, prolong the QT interval on ECG, particularly at higher doses or in patients with pre‑existing cardiac risk factors. The Patient should disclose any cardiac history or family history of sudden cardiac death.

§6.10 Seizures

Mirtazapine may lower the seizure threshold. Patients with epilepsy or a history of seizures should disclose this. Dose adjustments or alternative treatment may be required.

§6.11 Allergic reactions

Rare allergic reactions including rash, urticaria, and very rarely angioedema have been reported. The Patient must seek urgent care for swelling of face/tongue/throat or difficulty breathing.

§7 CONTRAINDICATIONS AND PRECAUTIONS

§7.1 Mirtazapine is contraindicated in:

  • Known hypersensitivity to mirtazapine or excipients
  • Concurrent use with MAO inhibitors (or within 14 days of discontinuation)

§7.2 Precautions — mirtazapine should be used with caution in patients with:

  • Epilepsy or history of seizures
  • Hepatic impairment (dose adjustment may be required)
  • Renal impairment (dose adjustment may be required)
  • Cardiac disease, QT prolongation risk factors, or family history of sudden cardiac death
  • Diabetes (mirtazapine may affect glucose control)
  • Urinary retention or prostatic hypertrophy
  • Narrow‑angle glaucoma
  • History of mania or bipolar disorder
  • History of substance abuse or dependence
  • Elderly patients (increased sensitivity, higher risk of falls)

§7.3 The Patient must disclose all relevant medical history including the conditions listed above.

§8 DRUG INTERACTIONS

§8.1 MAO inhibitors: Concurrent use is contraindicated. A washout period of at least 14 days is required.

§8.2 Serotonergic medications: Increased risk of serotonin syndrome when combined with:

  • SSRIs (e.g., sertraline, escitalopram, fluoxetine)
  • SNRIs (e.g., venlafaxine, duloxetine)
  • Triptans (migraine medications)
  • Tramadol
  • St. John's Wort (Hypericum perforatum)
  • Lithium

§8.3 Other CNS depressants: Additive sedation with:

  • Benzodiazepines
  • Opioid analgesics
  • Alcohol (see below)
  • Sedating antihistamines
  • Gabapentinoids (gabapentin, pregabalin)

§8.4 Alcohol: Mirtazapine potentiates the sedative effects of alcohol. The Patient should avoid or minimize alcohol consumption, particularly in the evening.

§8.5 CYP enzyme interactions: Mirtazapine is metabolized primarily by CYP3A4 and CYP1A2. Potent inhibitors (e.g., ketoconazole, fluvoxamine, ciprofloxacin) may increase mirtazapine levels; potent inducers (e.g., carbamazepine, rifampicin, phenytoin) may reduce efficacy.

§8.6 Warfarin: Mirtazapine may increase INR in patients taking warfarin. Monitoring is advised.

§8.7 The Patient has disclosed all current medications, supplements, and substances to the Prescribing Physician.

§9 ADMINISTRATION AND DOSING

§9.1 Typical low‑dose regimen for sleep and mood support:

  • Starting dose: 3.75–7.5 mg orally, 30–60 minutes before bedtime
  • Maintenance dose: 7.5–15 mg as tolerated and as clinically indicated
  • The lowest effective dose should be used

§9.2 Dose‑dependent pharmacology (important): The Patient understands that at low doses (≤15 mg), mirtazapine is predominantly sedating due to antihistamine activity. At higher doses (30–45 mg), noradrenergic effects increase and may paradoxically reduce sedation. For sleep support, lower doses are typically preferred.

§9.3 Timing: The medication should be taken 30–60 minutes before intended bedtime, with sufficient time allowed for 7–8 hours of sleep.

§9.4 Mirtazapine may be taken with or without food, though food may delay absorption slightly.

§10 MONITORING, FOLLOW‑UP, AND SAFETY COMMUNICATION

§10.1 The Clinic will monitor:

  • Sleep quality and patterns
  • Mood and psychological well‑being
  • Weight and metabolic parameters
  • Any adverse effects
  • Appropriateness of continued treatment

§10.2 The Patient agrees to follow‑up as advised, including an initial review within 2–4 weeks of starting treatment.

§10.3 The Patient agrees to promptly report: weight gain, worsening mood, suicidal thoughts, unusual bleeding or bruising, unexplained fever or sore throat, signs of infection, or any other concerning symptoms.

§11 ALTERNATIVE TREATMENTS

§11.1 Alternatives may include:

  • Cognitive Behavioral Therapy for Insomnia (CBT‑I): First‑line treatment for chronic insomnia with lasting benefits
  • Sleep hygiene optimization: Consistent schedule, dark/cool environment, blue light avoidance
  • Melatonin: Particularly for circadian rhythm issues
  • Other pharmacological options: Zolpidem (short‑term), doxepin (low dose), orexin antagonists
  • Psychotherapy for mood symptoms (cognitive behavioral therapy, counseling)
  • Lifestyle interventions: Exercise, stress management, circadian alignment
  • No pharmacological treatment

§11.2 The Patient confirms that alternatives have been discussed and understands the rationale for the proposed treatment.

§12 LIMITATION OF LIABILITY / NO GUARANTEE

§12.1 The Patient understands that medicine is not an exact science and no outcomes can be guaranteed.

§12.2 The Patient understands that adverse effects may occur despite appropriate prescribing and monitoring.

§12.3 Nothing in this consent excludes liability that cannot be excluded under applicable Danish law.

§13 WITHDRAWAL OF CONSENT

§13.1 The Patient may withdraw consent and discontinue treatment at any time by contacting the Clinic.

§13.2 If discontinuing after regular use, the Patient should consult the Clinic about gradual tapering to avoid discontinuation effects.

§14 DATA PROTECTION AND RECORDKEEPING

§14.1 The Patient's personal data and health information will be processed in accordance with GDPR and applicable Danish law.

§14.2 This consent may be retained as part of the Patient's medical record.

§15 ACKNOWLEDGMENTS AND DECLARATIONS

By consenting, the Patient confirms the following:

  • I have read this consent document in its entirety and understand its contents.
  • I understand that mirtazapine is being prescribed off‑label at a low dose for sleep support, sleep architecture improvement, and/or mild mood support, and that this is not an EMA‑approved indication for insomnia.
  • I understand that weight gain and increased appetite are common side effects and agree to monitor my weight.
  • I understand the risk of next‑day sedation and will not drive or operate machinery until I understand how the medication affects me.
  • I understand the rare but serious risk of serotonin syndrome if combined with other serotonergic medications, and the very rare risk of agranulocytosis (I will report unexplained fever, sore throat, or signs of infection).
  • I understand that mirtazapine should be tapered gradually and not stopped abruptly.
  • I understand that alcohol should be avoided or minimized, particularly in the evening, while taking mirtazapine.
  • I have disclosed all current medications, supplements, medical history, and any psychiatric history to the Clinic.
  • I have had the opportunity to ask questions and my questions have been answered.
  • I voluntarily consent to commence or continue treatment with the prescribed medication under the regimen agreed with my clinician.